Business Context and Reporting Period
Bioxcel Therapeutics, Inc. (BTAI), a Delaware corporation, filed this Form 8-K on March 10, 2026, to report the entry into a Material Definitive Agreement. The filing details a registered direct offering and a concurrent warrant amendment that closed on March 11, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.8 million.
- Securities Issued:
- 2,480,294 shares of Common Stock at $1.739 per share (including accompanying warrants).
- 2,020,491 Pre-Funded Warrants at $1.738 per share (including accompanying warrants).
- Warrant Terms: Accompanying warrants have an exercise price of $1.614 per share, are immediately exercisable, and expire five years from issuance.
- Placement Agent Fees:
- Cash fee: 6.0% of gross proceeds.
- Warrant fee: Warrants to purchase 180,031 shares (4.0% of aggregate shares placed) at an exercise price of $2.0175 per share.
- Expense reimbursement: Up to $75,000 plus up to $15,950 for clearing and closing expenses.
- Warrant Amendment Consideration: The investor paid approximately $173,135 for the reduction of exercise prices and term extension of existing warrants.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with a Purchaser to raise capital. Concurrently, the Company executed a Warrant Amendment Agreement regarding outstanding warrants issued in March and November 2024 covering 1,385,083 shares. Under this amendment:
- The exercise price was reduced to $1.614 per share.
- The term was extended to five years following the closing date of the Offering.
- The Placement Agent received a cash fee equal to 6.0% of the gross proceeds paid for the warrant amendment.
This filing does not provide comparative financial metrics (revenue, profit, cash flow, or debt levels) as it is a current report focused on a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard legal disclaimers. The transaction is subject to customary representations, warranties, and indemnification obligations. The Company noted that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the dilution impact of issuing 4,500,785 new equity instruments (shares and pre-funded warrants) plus 180,031 placement agent warrants.
- Confirm the net proceeds after deducting the 6.0% cash fee, expense reimbursements, and the $173,135 paid for the warrant amendment.
- Review the impact of the warrant amendment on the Company's existing capital structure and potential future dilution from the 1,385,083 amended warrants.
- Check the Company's cash runway post-offering given the biotech sector's typical burn rate, as no operating cash flow data is provided in this filing.